Recently, this hypothesis was confirmed in the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial, in which the IL-1β antagonism was able to reduce CVD in participants with previous myocardial infarction and high CRP levels, confirming the role of inflammation in CVD [30]. This evidence concerns the gene CRP and Venous thrombosis.